September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar
Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.
ADA Standards of Care in Diabetes 2024: A Guideline Topline
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D
Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.
Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose
Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose
Abbott Secures FDA Clearance for OTC CGMs for General Public, Adults with T2D Who do not Use Insulin
Abbott becomes the second company to receive FDA clearance for an over-the-counter continuous glucose monitoring system.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Death in Persons with CKD, T2D: Daily Dose
GLP-1RAs, SGLT-2 Inhibitors Tied to Lower Adverse Cardiovascular and Liver Events in Persons with T2D, MASLD
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
GLP-1RAs Linked to Lower Risk for Cirrhosis in Patients with MASLD, Type 2 Diabetes: Daily Dose
Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose
GLP-1 Agonists Reduce Risk of Cirrhosis, HCC in Adults with MASLD and T2D
DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.
New Study Shows Men with Diabetes Have Higher Risk of Disease-related Complications than Women
Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.
Roche Says Investigational Once-Weekly "Twincretin" Shows Promise in Adults with Obesity in Early Stage Clinical Trial
In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.
Cardiovascular-Kidney-Metabolic Syndrome in the US: Daily Dose
Lilly's Once-A-Week Insulin Demonstrates Safety, HbA1c Lowering Consistent with Daily Insulin
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
FDA Reports More than 200 Injuries Related to Recalled Tandem Diabetes Insulin App
There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.
Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study
Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
American Liver Foundation Announces First Federally-Funded Research on MASLD
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose
ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.